Navigation Links
Pharma IQ's Solubility Report
Date:4/27/2012

LONDON, April 27, 2012 /PRNewswire/ --

Pharma IQ has just published the results of an industry-wide Solubility Report, conducted recently among 3,000 pharmaceutical solubility specialists.

The results showed that improving API solubility is the greatest challenge for nearly 60% of respondents, followed by exploring novel drug delivery routes (specified by 26% of respondents). The rest of the survey participants indicated improving API stability and formulation of biopharmaceuticals as the major issues.

In terms of improving compound solubility, the most popular compound modification strategies used by respondents were developing an amorphous form and adding an excipient. The least popular ones were changing the crystal structure and addition of a salt.

The report was created as a part of the pre-conference research for Improving Solubility Forum, taking place 26-28 June, 2012 in Munich.

The results helped to shape the agenda and final speaker line-up, which features David Elder, Externalisation Director from GlaxoSmithKline who will present his thoughts on model guided formulation development and Lennart Lindfords, Pharmaceutical and Analytical R&D from AstraZeneca, who will be leading a session on Computer Calculations of Poorly Soluble Drug Transport Across the Gastrointestinal Cell Wall.

Other important topics expressed by survey respondents and that will be discussed at the event include:

  • The Impact of Solubility During Pharmaceutical Research and Development (Christoph Saal, Senior Manager Molecule Characterisation, Merck)
  • The impact of surfactants on dissolution, in-vitro permeability and bioavailability of poorly soluble drugs (Menno Vliestra, Global Supply Chain, Finance and HR, Roche)
  • The use the knowledge and exp
    '/>"/>

SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... 3, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... collaboration to discover and develop antisense therapies for ... builds on a broad existing relationship between the ... these therapeutic areas using novel RNA-targeted treatments. It ... its antisense technology to diseases of the kidney. ...
(Date:8/2/2015)... -- Mandatory takeover offer for the ... the "Company") is pleased to announce the signing of ... Marijan Han žeković to acquire his 63.3% holding (equivalent ... Croatian listed pharmaceutical business.   Dechra is ... €51.4 million for the entire share capital on a ...
(Date:8/2/2015)... 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... 3 clinical trial met its primary endpoint, showing ... cancer patients with carcinoid syndrome that is not ... Telotristat etiprate was discovered using Lexicon,s gene science, ... company,s first discovery to complete a pivotal Phase ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... 16 Westside Medical Associates of Los Angeles ... announce the benefit of early positron emission tomography ... treatable phase. According to Dr. Norman Lepor , Professor of ... and Co-director of Imaging at WMI, "the research investigators at the ...
... American pharmaceutical manufacturer Alpharma Inc. has agreed to pay ... in connection with the marketing of the morphine-based drug, Kadian, ... between January 1, 2000 and December 29, ... to promote or prescribe Kadian, and made misrepresentations about the ...
Cached Medicine Technology:Early Identification of Alzheimer's Disease With PET Scan 2Early Identification of Alzheimer's Disease With PET Scan 3Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 3
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular ... IBAM NA’s cyclotron sites and research and development facilities. , “We are ... as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO ...
(Date:8/3/2015)... ... 2015 , ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility ... opening in August. The new facility is licensed under Dignity Health Arizona ... “Dr. Baldwin is an excellent leader and will ensure our new freestanding emergency room ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... firm, announced today that Joe Williams has joined its growing California employee benefits ... HUB's differentiated service model to his clients. Mr. Williams will be joining the ...
(Date:8/3/2015)... Miami, Florida (PRWEB) , ... August 03, 2015 , ... ... neuropathy pain accompanied by tissue injury caused by diabetes after many years of suffering ... work many times, and he didn’t want to ask for extra time off or ...
(Date:8/3/2015)... ... 03, 2015 , ... Cambia Health Solutions has promoted Scott ... company’s Medicare and Federal Employee Programs (FEP) lines of business. , Government ... members. In this role, Scott is responsible for overseeing the growth, finance and ...
Breaking Medicine News(10 mins):Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... Heart Institute is the lead enroller in the world for ... repair for severe mitral valve regurgitation with conventional surgery. In ... first Evalve MitraClip in California, and was also first on ... procedure. Cedars-Sinai is believed to be the most experienced center ...
... debate continues on whether the nutrient should be recommended for ... patients with high blood levels of vitamin D boost their ... , Previous studies have indicated that high levels of vitamin ... 51 percent, although other studies dispute that claim. But until ...
... Senior,Living Inc. (NYSE: BKD ) announced today that ... 2008 Jefferies Healthcare,Conference in New York, New York on ... The presentation is being webcast live and can be ... at, http://www.brookdaleliving.com . A replay of the webcast will ...
... Adds $47 million in annual revenues and eight locations in New ... Connecticut, and ... AFAM ), a leading regional provider of home health nursing,services, ... stock of Patient Care, Inc. This acquisition, the Company,s,largest to date, ...
... Message to Fans, TALLAHASSEE, Fla., June 19 ... top-ranked Florida Marlins and Tampa Bay,Rays are leading a ... Free Florida, an initiative of the Florida Department of,Health, ... Floridians with,its messages of smoking and smokeless tobacco prevention ...
... 19 /PRNewswire-FirstCall/,-- Cord Blood America, Inc. (OTC ... cell preservation company ( http://www.cordblood-america.com ),focused ... stem cells to families,nationwide and internationally, today ... in enacting legislation requiring health care facilities ...
Cached Medicine News:Health News:Evalve MitraClip: Clinical trial of nonsurgical repair for severe mitral valve regurgitation 2Health News:Vitamin D May Promote Colon Cancer Survival 2Health News:Vitamin D May Promote Colon Cancer Survival 3Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 2Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 3Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 4Health News:Rivalry Aside, Marlins and Rays Team Up To Fight Tobacco 2Health News:Cord Blood America Says Pennsylvania Joins New York and California in Informing Parents of the Advantages of Umbilical Cord Blood Storage 2
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
... design provides fingertip ratchet disengagement allowing smooth, ... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ...
Medicine Products: